Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Rhb-107
2. Upamostat
3. Wx-671
1. Upamostat
2. Upamostat [inn]
3. 1191101-18-4
4. S5m7kw6u17
5. 1-piperazinecarboxylic Acid, 4-((2s)-3-(3-((e)-amino(hydroxyimino)methyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, Ethyl Ester
6. Ethyl 4-((2s)-3-{3-((e)-n'-hydroxycarbamimidoyl)phenyl)-2-(2,3,5-tri(propan-2-yl)benzenesulfonamido)propanoyl)piperazine-1-carboxylate
7. Ethyl 4-[(2s)-3-[3-[(e)-n'-hydroxycarbamimidoyl]phenyl]-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate
8. Unii-s5m7kw6u17
9. Wx-671
10. Ethyl 4-((2s)-3-(3-((e)-n'-hydroxycarbamimidoyl)phenyl)-2-(2,3,5-tri(propan-2-yl)benzenesulfonamido)propanoyl)piperazine-1-carboxylate
11. Upamostat [who-dd]
12. Schembl12618906
13. Schembl20669283
14. 590368-25-5
15. Ex-a6355
16. Wx-671wx-671
17. Db13052
| Molecular Weight | 629.8 g/mol |
|---|---|
| Molecular Formula | C32H47N5O6S |
| XLogP3 | 5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 12 |
| Exact Mass | 629.32470541 g/mol |
| Monoisotopic Mass | 629.32470541 g/mol |
| Topological Polar Surface Area | 163 Ų |
| Heavy Atom Count | 44 |
| Formal Charge | 0 |
| Complexity | 1070 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
RHB-107, a proprietary, first-in-class, once-daily orally administered investigational antiviral, is currently undergoing mid-stage clinical trials for treating Covid-19.
Lead Product(s): Upamostat,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 24, 2024
Lead Product(s) : Upamostat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
Details : RHB-107, a proprietary, first-in-class, once-daily orally administered investigational antiviral, is currently undergoing mid-stage clinical trials for treating Covid-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 24, 2024
Details:
RHB-107 (Upamostat) is a serine protease inhibitor small molecule drug candidate, which is currently being evaluated in combination with remdesivir for the treatment of Ebola.
Lead Product(s): Upamostat,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2023
Lead Product(s) : Upamostat,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RHB-107 (Upamostat) is a serine protease inhibitor small molecule drug candidate, which is currently being evaluated in combination with remdesivir for the treatment of Ebola.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2023
Details:
The finding aims to support RedHill to focus on the development of RHB-107 (upamostat), a potent inhibitor of serine proteases. It is being evaluated in the treatment of early outpatientand post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2.
Lead Product(s): Upamostat,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Henry M. Jackson Foundation
Deal Size: $4.8 million Upfront Cash: Undisclosed
Deal Type: Funding December 04, 2023
Lead Product(s) : Upamostat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Henry M. Jackson Foundation
Deal Size : $4.8 million
Deal Type : Funding
Details : The finding aims to support RedHill to focus on the development of RHB-107 (upamostat), a potent inhibitor of serine proteases. It is being evaluated in the treatment of early outpatientand post-exposure prophylaxis for Severe Acute Respiratory Syndrome ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 04, 2023
Details:
RHB-107 (upamostat) is a proprietary, first-in-class, once-daily orally administered investigational antiviral, that targets human serine proteases involved in preparing the spike protein for viral entry into target cells.
Lead Product(s): Upamostat,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 31, 2023
Lead Product(s) : Upamostat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RHB-107 (upamostat) is a proprietary, first-in-class, once-daily orally administered investigational antiviral, that targets human serine proteases involved in preparing the spike protein for viral entry into target cells.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2023
Details:
Upamostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of SARS-CoV-2.
Lead Product(s): Upamostat,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: JPEO CBRND Enabling Biotechnologies | RedHill Biopharma | FHI Clinical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2023
Lead Product(s) : Upamostat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : JPEO CBRND Enabling Biotechnologies | RedHill Biopharma | FHI Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
Details : Upamostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 20, 2023
Details:
RHB-107 (Upamostat) is a proprietary, first-in-class, once-daily orally administered investigational antiviral, that targets human serine proteases involved in preparing the spike protein for viral entry into target cells.
Lead Product(s): Upamostat,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 03, 2023
Lead Product(s) : Upamostat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RHB-107 (Upamostat) is a proprietary, first-in-class, once-daily orally administered investigational antiviral, that targets human serine proteases involved in preparing the spike protein for viral entry into target cells.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 03, 2023
Details:
Phase 2 part of Phase 2/3 study of RHB-107 (upamostat), orally-administered antiviral, that targets human serine proteases in symptomatic COVID-19 successfully met study's primary endpoint showing good safety, tolerability and highly promising efficacy results.
Lead Product(s): Upamostat,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 01, 2022
Lead Product(s) : Upamostat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
Details : Phase 2 part of Phase 2/3 study of RHB-107 (upamostat), orally-administered antiviral, that targets human serine proteases in symptomatic COVID-19 successfully met study's primary endpoint showing good safety, tolerability and highly promising efficacy r...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2022
Details:
Opaganib is a novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated dual anti-inflammatory and antiviral activity, targeting a human cell component involved in viral replication.
Lead Product(s): Upamostat,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 22, 2021
Lead Product(s) : Upamostat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Opaganib is a novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated dual anti-inflammatory and antiviral activity, targeting a human cell component involved in viral replication.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 22, 2021
Details:
This U.S. Phase 2/3 study will examine the safety and efficacy of RedHill Biopharma's RHB-107 (upamostat), using ObvioHealth's clinical trial ecosystem, including digital devices, a patient-centric smartphone application and home healthcare visits.
Lead Product(s): Upamostat,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: RedHill Biopharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 02, 2021
Lead Product(s) : Upamostat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : RedHill Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This U.S. Phase 2/3 study will examine the safety and efficacy of RedHill Biopharma's RHB-107 (upamostat), using ObvioHealth's clinical trial ecosystem, including digital devices, a patient-centric smartphone application and home healthcare visits.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 02, 2021
Details:
Upamostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Lead Product(s): Upamostat,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 25, 2021
Lead Product(s) : Upamostat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Details : Upamostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
74
PharmaCompass offers a list of Upamostat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Upamostat manufacturer or Upamostat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Upamostat manufacturer or Upamostat supplier.
PharmaCompass also assists you with knowing the Upamostat API Price utilized in the formulation of products. Upamostat API Price is not always fixed or binding as the Upamostat Price is obtained through a variety of data sources. The Upamostat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Upamostat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Upamostat, including repackagers and relabelers. The FDA regulates Upamostat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Upamostat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Upamostat supplier is an individual or a company that provides Upamostat active pharmaceutical ingredient (API) or Upamostat finished formulations upon request. The Upamostat suppliers may include Upamostat API manufacturers, exporters, distributors and traders.
Upamostat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Upamostat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Upamostat GMP manufacturer or Upamostat GMP API supplier for your needs.
A Upamostat CoA (Certificate of Analysis) is a formal document that attests to Upamostat's compliance with Upamostat specifications and serves as a tool for batch-level quality control.
Upamostat CoA mostly includes findings from lab analyses of a specific batch. For each Upamostat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Upamostat may be tested according to a variety of international standards, such as European Pharmacopoeia (Upamostat EP), Upamostat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Upamostat USP).
